Regular Aspirin-Use Preceding the Onset of Primary Intracerebral Hemorrhage is an Independent Predictor for Death

Pertti Saloheimo, MD; Mikko Ahonen, MD; Seppo Juvela, MD, PhD; Juhani Pyhtinen, MD, PhD; Eeva-Riitta Savolainen, MD, PhD; Matti Hillbom, MD, PhD

Background and Purpose—Hematoma volume and impaired level of consciousness are the most potent predictors of outcome after spontaneous intracerebral hemorrhage (ICH). The effect of preceding aspirin-use on outcome after ICH is poorly investigated. We investigated short-term mortality and hematoma enlargement in subjects with ICH to find the predictors for these outcomes.

Methods—This population-based study included all subjects with ICH during a period of 33 months in the population of Northern Ostrobothnia, Finland. The subjects were identified, and their clinical characteristics and outcomes were checked from hospital records or death records.

Results—Three-month mortality of the 208 identified subjects with ICH was 33%. The independent risk factors for death were regular aspirin-use at the onset of ICH (relative risks [RR], 2.5; 95% CI, 1.3 to 4.6; \( P = 0.004 \)), warfarin-use at the onset of ICH (RR, 3.2; 95% CI, 1.6 to 6.1; \( P = 0.001 \)), and ICH score higher than 2 on admission (RR, 13.8; 95% CI, 6.0 to 31.4; \( P < 0.001 \)). Regular aspirin-use preceding the onset of ICH associated significantly with hematoma enlargement during the first week after ICH (\( P = 0.006 \)).

Conclusions—We observed poor short-term outcomes and increased mortality, probably attributable to rapid enlargement of hematomas, in the subjects with ICH who had been taking regularly moderate doses of aspirin (median 250 mg) immediately before the onset of the stroke. (Stroke. 2006;37:129-133.)

Key Words: aspirin ■ cerebral hemorrhage ■ mortality ■ warfarin

Independent predictors of short-term mortality (30 days) after spontaneous intracerebral hemorrhage (ICH) include the size and location of the hemorrhage, a midline shift in head computed tomography (CT), intraventricular spread of the hemorrhage, low Glasgow Coma Scale (GCS) score on admission, and high blood glucose and blood pressure on admission.\(^1\)\(^-\)\(^6\) Preceding medication and hematologic abnormalities may also predict the outcome, but their independent roles are less clear.

Many reports have demonstrated that patients on warfarin show a high mortality rate (52% to 68%) attributable to rapid enlargement of their hematomas.\(^7\)\(^-\)\(^8\) Use of antiplatelet agents has not been shown to exert a similar effect, but as far as we know, only a few studies have been reported.\(^8\)\(^-\)\(^10\) To resolve the role of aspirin, in particular, we investigated outcome and hematoma enlargement in a population-based cohort of patients with ICH.

Methods

We identified all subjects with ICH between January 1993 and September 1995 in the population of Northern Ostrobothnia, Finland. The study included all patients admitted into Oulu University Hospital for ICH during this period. Oulu University Hospital is the only hospital serving acute stroke patients in the area (population 356,026). ICH was verified by a head CT scan on admission in all cases. We excluded patients not living in the catchment area of the hospital and those with a brain tumor, aneurysm, vascular malformation, hematologic malignancy, hemophilia, or head trauma. The fatal cases of ICH in the community during the study period were identified from death records (Statistics Finland), but cases without verification of ICH at autopsy or by brain imaging were excluded. The study protocol was approved by the ethics committee of the hospital.

Information about previous diseases, blood pressure histories, medications, and smoking were extracted from the hospital records. Data were extracted from the forensic autopsy charts of those who had succumbed on the scene. Cardiac complications, infection, deep vein thrombosis, or pulmonary embolus during hospitalization were recorded, as were also neurosurgical interventions. The time of ICH onset was defined to be the acute onset of headache or a neurological deficit.

The subjects were considered to be hypertensive if their blood pressure readings preceding the index stroke had repeatedly exceeded 160/95 mm Hg, or if they were taking antihypertensive medication. The patients were recorded as having diabetes mellitus if they used oral hypoglycemic agents or insulin. Previous hemorrhagic
and ischemic strokes were recorded. Cardiac disease included myocardial infarction, coronary artery disease, heart failure, and atrial fibrillation. Gastrointestinal bleeding and hematuria in the patients' history were recorded. Subjects were categorized into current cigarette smokers and nonsmokers.

The ICH score was calculated on the basis of the GCS score on admission, volume, supra- or infratentorial location and ventricular extension of the hematoma, and the patient's age. The scores were classified into 3 categories: zero (0 points), low (1 to 2 points), and high (3 to 6 points). The patients' survival during the first 3 months after the onset of ICH was checked from hospital records and death records. Functional outcome at 3 months was assessed according to the Glasgow Outcome Scale on scheduled control visits.

Possible enlargement of the hematoma was assessed in the patients who received a second CT scan within a week after the onset and the Pearson test, and the test for significance was based on changes in log (partial) likelihood. A 2-tailed probability value of <0.05 was considered to be statistically significant.

**Results**

We found altogether 208 subjects with a verified spontaneous ICH during the study period, and the crude annual incidence rate was 21/100,000. The baseline characteristics of the subjects are shown in Table 1. Two hundred and three patients were admitted into our hospital, and the diagnosis was verified by a head CT scan. Five subjects succumbed elsewhere, and their diagnoses were verified at autopsy. The aspirin users were significantly older than nonusers of aspirin/warfarin (P = 0.004). History of cardiac disease (P < 0.01) and ischemic stroke (P < 0.01) were more common in the group of aspirin/warfarin users than in the nonuser group.

The clinical characteristics and outcomes are shown in Table 2. On admission, aspirin users did not have larger hematomas than nonusers of aspirin/warfarin, but warfarin users had significantly larger hematomas than aspirin users (P = 0.015) and nonusers of aspirin/warfarin (P = 0.012). CT scanning was performed on the day of symptom onset in 73% of aspirin users, 76% of warfarin users, and 70% of nonusers of aspirin/warfarin. The groups differed significantly by outcome at 3 months (P < 0.001) and bleeding into the ventricles (P = 0.001), the latter finding being most frequent in warfarin users. In the 47 patients with ICH score >2, 55% had GCS score 3 to 4, 40% had GCS score 5 to 12, 74% had hematoma volume ≥30 cm³, 89% had intraventricular and 13% had infratentorial hemorrhage, and 28% were aged ≥80 years.

The primary bleed was the cause of death in 17 (89%) of the 19 fatalities in the group of aspirin users. The 2 others died of pneumonia and pulmonary embolism. Among warfarin users, the cause of death was the primary bleed in 18 cases (95%), and 1 patient died of thrombosis of the abdominal
A second CT scan was available for 104 patients. Median time interval between the baseline and the second CT scan was 7 days (25th and 75th percentiles, 4 and 9). Regular aspirin-use preceding the onset of ICH associated significantly with relative hematoma growth (by percent; \(P=0.005\); Mann-Whitney U-test). We also dichotomized hematoma enlargement as previously reported (\(\geq 33\%\)).9,15 In this analysis, the association of aspirin-use with hematoma enlargement did not reach statistical significance, probably attributable to the limited number of aspirin users with a second CT scan. Most warfarin users had large hematomas preceding the onset of ICH associated significantly with relative hematoma growth (by percent; \(P=0.006\); Mann-Whitney U-test). We also dichotomized hematoma enlargement as previously reported (\(\geq 33\%\)).9,15 This population-based study indicated that regular aspirin use was a significant independent predictor for death within the first 3 months after the onset of ICH. This is a novel finding. Other significant predictors for death during the first 3 months after the onset of ICH are shown in Table 3.

The cumulative survival rates are shown in the Figure. Overall mortality within 3 months was 32.7%. The mortality rates of aspirin users, warfarin users and nonusers of aspirin/warfarin were 43.2%, 73.1% and 21.7%, respectively. The log-rank test revealed significant differences between the survival curves of aspirin users and nonusers of aspirin/warfarin (\(P=0.0048\)) as well as between warfarin users and nonusers of aspirin/warfarin (\(P<0.0001\)) and between aspirin users and warfarin users (\(P=0.0026\)). Univariate and multivariate RRs of the significant predictors of death during the first 3 months after the onset of ICH are shown in Table 3. The median daily dose of aspirin used was 250 mg (range, 50 to 500). There was no significant difference in the aspirin doses of the patients who died within 3 months after their ICH and of those who survived (\(P=0.58\)). Nor were there significant differences in mean platelet count between the study groups or between the survivors and those who died. The mean international normalized ratio (INR) of warfarin users on admission was 3.8±1.8 (range 1.5 to 7.8). The difference between the INRs of the warfarin users who died within the first 3 months after ICH and of the survivors was not significant (\(P=0.43\)).

**Discussion**

This population-based study indicated that regular aspirin use before the onset of primary ICH was a significant independent predictor for death within the first 3 months after the index stroke. This is a novel finding. Other significant predictors for death were warfarin-use and a high ICH score on admission.

We found 2-fold 3-month-mortality in aspirin users compared with nonusers of aspirin/warfarin. The deaths of aspirin

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No Aspirin or Warfarin (n=138)</th>
<th>Aspirin Users (n=44)</th>
<th>Warfarin Users (n=26)</th>
<th>Total (n=208)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median volume of ICH, mL (25th and 75th percentiles)</td>
<td>20 (7, 39)</td>
<td>16 (6, 48)</td>
<td>50 (16, 112)</td>
<td>21 (7, 45)</td>
</tr>
<tr>
<td>Intraventricular hemorrhage (%)</td>
<td>54 (39)</td>
<td>11 (25)</td>
<td>18 (69)</td>
<td>83 (40)</td>
</tr>
<tr>
<td>Mean MAP*, mm Hg (SD)</td>
<td>126 (24)</td>
<td>127 (21)</td>
<td>132 (22)</td>
<td>127 (23)</td>
</tr>
<tr>
<td>Mean blood glucose on admission, mmol/L (SD)</td>
<td>8.0 (3.7)</td>
<td>8.9 (4.7)</td>
<td>9.9 (8.6)</td>
<td>8.4 (4.8)</td>
</tr>
<tr>
<td>Mean platelet count on admission, 10³/μL (SD)</td>
<td>264.4 (79.0)</td>
<td>261.8 (68.7)</td>
<td>247.4 (63.0)</td>
<td>262.0 (75.0)</td>
</tr>
<tr>
<td>Location of hematoma, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subcortex</td>
<td>44 (32)</td>
<td>10 (23)</td>
<td>9 (35)</td>
<td>63 (30)</td>
</tr>
<tr>
<td>Basal ganglia (and combined†)</td>
<td>59 (43)</td>
<td>20 (45)</td>
<td>11 (42)</td>
<td>90 (43)</td>
</tr>
<tr>
<td>Thalamus</td>
<td>15 (11)</td>
<td>6 (14)</td>
<td>3 (12)</td>
<td>24 (12)</td>
</tr>
<tr>
<td>Cerebellum and pons</td>
<td>20 (14)</td>
<td>8 (18)</td>
<td>3 (12)</td>
<td>31 (15)</td>
</tr>
<tr>
<td>ICH Score, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>38/132 (29)</td>
<td>14/43 (33)</td>
<td>4/24 (17)</td>
<td>56/199 (28)</td>
</tr>
<tr>
<td>1 to 2</td>
<td>69/132 (52)</td>
<td>20/43 (47)</td>
<td>7/24 (29)</td>
<td>96/199 (48)</td>
</tr>
<tr>
<td>&gt;2</td>
<td>25/132 (19)</td>
<td>9/43 (21)</td>
<td>13/24 (54)</td>
<td>47/199 (24)</td>
</tr>
<tr>
<td>Glasgow Outcome Scale at 3 mo, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Good recovery</td>
<td>39 (28)</td>
<td>11 (25)</td>
<td>2 (8)</td>
<td>52 (25)</td>
</tr>
<tr>
<td>Moderate disability</td>
<td>24 (17)</td>
<td>2 (5)</td>
<td>1 (4)</td>
<td>27 (13)</td>
</tr>
<tr>
<td>Severe disability or vegetative state‡</td>
<td>45 (33)</td>
<td>12 (27)</td>
<td>4 (15)</td>
<td>61 (29)</td>
</tr>
<tr>
<td>Dead</td>
<td>30 (22)</td>
<td>19 (43)</td>
<td>19 (73)</td>
<td>68 (33)</td>
</tr>
<tr>
<td>Enlargement of hematoma§, n (%)</td>
<td>6/78 (8)</td>
<td>4/21 (19)</td>
<td>1/5 (20)</td>
<td>11/104 (11)</td>
</tr>
<tr>
<td>Mean enlargement of hematoma, % (SD)</td>
<td>4.8 (16.1)</td>
<td>12.8 (22.6)</td>
<td>10.6 (16.8)</td>
<td>6.7 (17.7)</td>
</tr>
</tbody>
</table>

*Mean arterial blood pressure on admission; †Extension of putaminal hematoma into thalamus and subcortical white matter; ‡No one remained in a vegetative state; §By \(\geq 33\%\).
users were attributable to ICH, except in 2 cases. On admission, aspirin-related hemorrhages were of the same size as those seen in nonusers of aspirin/warfarin. Other investigators have also reported that the baseline hematoma size in patients using platelet-inhibiting drugs is no greater than that in patients not using such drugs.9 In our study, aspirin-use significantly associated with hematoma growth, which has been shown to be an independent factor increasing mortality after ICH.16

We believe that the untoward effect of aspirin-use on short-term outcome was attributable to early enlargement of hematomas in aspirin users. However, we were unable to prove this hypothesis because a second CT scan was available for only 104 patients. On the other hand, mortality during the first 4 days after the onset of ICH was higher (18%) in aspirin users than in nonusers of aspirin/warfarin (11%), despite the fact that aspirin users did not have larger hematomas on admission than nonusers of aspirin/warfarin. The cause of death in these cases may have been early hematoma growth. Alternatively, use of aspirin may have emerged as a risk factor for death after ICH attributable to a proximal effect of several factors associated with its use, like patient age, diabetes and history of cardiac disease and ischemic stroke, although these were not solitary independent risk factors.

Previous studies have not found recent use of antiplatelet agents to associate with an increased risk of hematoma expansion9 or higher mortality.8–10 However, in the 2 hospital-based studies,8,9 the most potent antiplatelet drug, aspirin, was not distinguished from other nonsteroidal anti-inflammatory drugs (NSAIDs). In the population-based study by Nilsson et al,10 a nonsignificant trend for aspirin to predict mortality may be seen after omitting warfarin users. In the Swedish Aspirin Low-dose Trial (SALT), there was a significant increase in the risk of fatal hemorrhagic strokes among the aspirin (75 mg/day) users.17 A plausible explanation for the increased mortality of aspirin users would be more frequent hematoma enlargement caused by impaired hemo- stasis during the first few days after the onset of ICH. We recently observed prolonged bleeding times on admission in ICH patients who had been using aspirin, and even after the discontinuation of aspirin, the effect of the drug on hemo- stasis continued for a few days.18 The high 3-month mortality in warfarin users reflects the facts that most of them showed large hematomas on admission and no effective measure to reverse the anticoagulant effect was used.

Hematoma volume is a potent predictor of mortality and functional outcome.2,4,5,11 Decreased blood coagulability,19,20 increased blood pressure,8 liver disease,20 insufficient thrombin generation,19 and elevated INR value20 may all foster hematoma enlargement. This list may also include insufficient platelet function induced by aspirin, but the risk of aspirin-use should be weighed against each individual’s need for medication and the possible risks of alternative medications. It has been suggested that ongoing enlargement of ICH might be detected on the basis of extravasation of radiographic contrast into the hematoma after CT angiography.21

TABLE 3. Predictors for Death Within the First 3 Months After ICH

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate RR (95% CI)</th>
<th>Multivariate RR* (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICH Score &gt;2 on admission</td>
<td>14.5 (6.5–32.5)†</td>
<td>13.8 (6.0–31.4)†</td>
</tr>
<tr>
<td>Warfarin use preceding ICH</td>
<td>3.9 (2.1–7.2)†</td>
<td>3.2 (1.6–6.1)‡</td>
</tr>
<tr>
<td>Regular aspirin use preceding ICH</td>
<td>2.5 (1.4–4.6)‡</td>
<td>2.5 (1.3–4.6)‡</td>
</tr>
<tr>
<td>Diabetes</td>
<td>2.4 (1.2–4.8)§</td>
<td>2.1 (0.99–4.3)</td>
</tr>
</tbody>
</table>

*RRs have been adjusted for age, sex, and the variables listed in the table; †P<0.001; ‡P<0.01; §P<0.05.
Our findings suggest that prevention of hematoma growth may be needed if aspirin has been used by the ICH patient. In patients on warfarin, emergent reversal of anticoagulation is needed as quickly as possible.7 In aspirin-associated ICH, reversal of the antiplatelet effect of aspirin by platelet transfusions could be attempted. Platelet transfusion has been recommended in life-threatening ICH attributable to autoimmune thrombocytopenia.22 However, we need further studies to prove that early hematoma growth leads to increased mortality in aspirin users and that platelet transfusion is efficient and safe as a preventive measure.

The strength of our study is that it was based on a defined population. We included all patients admitted into our hospital because of ICH during the study period, without selection based on, for example, the delay before CT scanning. Because there are no other hospitals in the area admitting acute stroke patients, and such patients are recommended to be immediately referred to our hospital, we believe we were able to avoid selection bias. In addition, we identified the subjects with ICH who died during the study period without ever reaching the hospital. Of these, we included only the patients with ICH confirmed at autopsy. However, the strict inclusion criteria may result in underestimation of the real incidence rate of spontaneous ICH in the population. The lack of systematic second CT scanning of the patients who died soon after the index stroke is a limitation of the study. Those with only a single CT scan had significantly higher mortality (79.4% versus 20.6%) than those with several CT scans. This is likely to result in underestimation of the frequency of hematoma expansion in the cohort. Also, the delay between symptom onset and the first CT scan was rather crudely estimated. The use of 10 mm CT sections in the supratentorial region introduces a degree of measurement error. On the other hand, the imaging protocol was the same in all primary and repeat scans, which are thus comparable. We did not record occasional use of aspirin, which is another limitation. Consequently, some patients classified as nonusers of aspirin/warfarin may have ingested aspirin just before the stroke, which may have worsened their outcome. Such misclassification might underestimate aspirin-associated mortality.

In conclusion, aspirin doubled the 3-month mortality of ICH patients compared with nonusers of aspirin/warfarin. Aspirin-use also associated with early hematoma growth. The observations allow us to hypothesize that aspirin-use may predispose to hematoma enlargement. Whether the benefits of interventions such as platelet transfusion outweigh the risks in aspirin-associated ICH requires further study.

Acknowledgments
The study was supported in part by the Neurology Foundation, Finland (P.S.).

References
Regular Aspirin-Use Preceding the Onset of Primary Intracerebral Hemorrhage is an Independent Predictor for Death
Pertti Saloheimo, Mikko Ahonen, Seppo Juvela, Juhani Pyhtinen, Eeva-Riitta Savolainen and Matti Hillbom

Stroke. 2006;37:129-133; originally published online December 1, 2005; doi: 10.1161/01.STR.0000196991.03618.31
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2005 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/37/1/129

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org/subscriptions/